Exelixis (EXEL) Tops Q2 EPS by 11c, provides guidance
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $54.08 +0.73%
Financial Fact:
Restructuring charge: 1.02M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Restructuring charge: 1.02M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q2 EPS of $0.75, $0.11 better than the analyst estimate of $0.64. Revenue for the quarter came in at $568.3 million versus the consensus estimate of $578.46 million.
GUIDANCE:
Exelixis sees FY2025 revenue of $2.25-2.35 billion, versus the consensus of $2.341 billion.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Wolfe Research sees CNH stock flat 2027 outlook on commodity prices
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
